Strategies to investigate the immunosuppressive effect of TGFβ specifically on NK-cell therapy are currently being tested clinically in patients with relapsed Ewing sarcoma (NCT05634369; ref. 36). Here, TGFB1 is linked to Ewing sarcoma.